Tag Archives: healthcare

EQT completes sale of shares in Galderma Group AG

eqt
  • The sale resulted in aggregate gross proceeds of c. CHF 1.3 billion, of which EQT received c. CHF 354 million

Further to previous announcements, an affiliate of the funds known as EQT VIII (“EQT”) is pleased to announce the completion of the placement of 15,000,000 shares in Galderma Group AG (SIX: GALD) (the “Company”) (the “Shares”) for aggregate gross proceeds of c. CHF 1.3 billion via an accelerated bookbuilding process (the “Placement”).  

As part of the Placement, EQT received gross proceeds of c. CHF 354 million. The Placement was completed on 13 March 2025. BNP Paribas, BofA Securities, Goldman Sachs, Morgan Stanley and UBS acted as joint global coordinators and joint bookrunners for the Placement. 

Contact
EQT Press Office, press@eqtpartners.com

Important notice
This press release does not constitute (i) an offer to sell or a solicitation of an offer to buy any securities of Galderma Group AG or any of its affiliates and it does not constitute a prospectus within the meaning of the Swiss Financial Services Act or (ii) an offer of securities for sale in the United States or elsewhere. Securities may not be offered or sold in the United States absent registration with the United States Securities and Exchange Commission or an exemption from registration. There will be no public offering of any of the securities mentioned in this press release in the United States

Downloads

About EQT
EQT is a purpose-driven global investment organization with EUR 269 billion in total assets under management (EUR 136 billion in fee-generating assets under management), within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com
Follow EQT on LinkedIn, X, YouTube and Instagram 

About Galderma Group AG
Galderma Group AG is a pure-play leader in the dermatology category, with a presence in approximately 90 countries. It delivers an innovative, science-based portfolio of premium flagship brands and services that cover the full spectrum of the rapidly growing dermatology market. This includes Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Since its foundation in 1981, Galderma has dedicated its focus and passion to the human body’s largest organ – the skin – addressing individual consumer and patient needs with superior outcomes in collaboration with healthcare professionals.

Categories: News

Tags:

Sencure Secures €7.9M to Revolutionize Wearable Health Tech

819 Capital Partners

Deventer, 11 March 2025 – Portfolio company Sencure, a leader in wearable health technology, has secured a €3.9 million additional investment in its Series B2 funding round, bringing the total B round up to € 7.9 million. Its total funding—including non-dilutive sources—amounts to over €15 million in the last 4 years.

 

At the heart of Sencure’s success is its flagship product, the SNCE800 IC —a high-performance, low-power chip that’s setting new standards for wearable medical devices. The SNCE800 is poised to power a new generation of wearable health products, from EEG-enabled earbuds and headbands to ECG patches and EMG-based wearables.

As the global demand for compact, efficient medical devices surges—driven by an aging population and rapid healthcare digitalization—Sencure’s innovations are leading the charge in creating smarter, more efficient solutions.

With investment backing from Cottonwood Technology Fund, Bluegrass Ventures, NV NOM, and 819 Capital Partners, Sencure is gearing up for a major expansion. Central to this growth is the opening of a state-of-the-art facility at the Noviotech Campus in Nijmegen. “We are thrilled to welcome Bluegrass Ventures to our family of investors and to strengthen our existing partnerships,” said Sencure CEO Dick van Waes. “This funding propels us into the next phase of growth and innovation.”

Sencure has also welcomed Getlin Visser to its Supervisory Board. With a deep-rooted passion for technology and healthcare innovation, Visser brings invaluable expertise to guide Sencure’s next steps. “I am excited to join Sencure’s Supervisory Board and support their mission to revolutionize wearable technology,” said Visser. “Their approach to healthcare solutions is visionary, and I look forward to being part of their journey.”

Additionally, the company’s newly appointed VP of R&D, William Trilsbeek, will spearhead efforts in Nijmegen. “Leading this team in Nijmegen is an incredible opportunity,” said Trilsbeek. “Sencure’s relentless pursuit of innovation is inspiring, and I’m eager to contribute to groundbreaking solutions that will shape the future of healthcare.”

With fresh capital, an expanded team, and cutting-edge technology, Sencure is well on its way to transforming the wearable health market. As the company continues its mission to miniaturize and enhance medical wearables, the future looks brighter than ever.

We invested in Sencure through 819 Evergreen Fund.

Categories: News

Tags:

FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility

GHO Capital
  • Acquisition of Charles River site, previously Distributed Bio, strengthens antibody discovery capabilities with SuperHuman libraries and Yeast Display platform
  • Established presence in major North American biotechnology cluster extends FairJourney’s global reach

London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company FairJourney Biologics regarding its acquisition of the South San Francisco site from Charles River Laboratories International, Inc.

FairJourney Biologics S.A., leaders in the discovery and optimisation of antibodies, announced that it had completed the acquisition of the South San Francisco site from Charles River Laboratories International, Inc. The acquisition aligns with FairJourney’s ongoing strategic growth plan, and will significantly bolster the Company’s antibody discovery and engineering capabilities, strengthening its technology portfolio and expanding its global presence with a key biotechnology hub in the US.

The acquisition of the South San Francisco site, formerly Distributed Bio, will transfer ownership of all facilities, staff and assets to FairJourney Biologics, including proprietary technologies such as the SuperHuman™, Cosmic™ and Tungsten™ libraries. By integrating these libraries within FairJourney’s own portfolio of antibody discovery technologies, the Company will offer customers a more diverse array of antibody discovery tools, and bring new antibody engineering solutions to its portfolio. Under the agreement, FairJourney will also acquire Charles Rivers’ Yeast Display method, allowing the Company to offer an expanded antibody discovery platform that can complement and enhance existing offerings.

South San Francisco hosts one of the world’s largest biotech clusters. Establishing facilities in this region forms a core part of the Company’s ongoing development strategy, strengthening its reach and physical presence in a major global market. The acquisition will provide customers in this region with a localised source of expertise and technical support, helping them to accelerate their antibody discovery and engineering pipelines. The deal will also enable FairJourney to leverage the industry-leading scientific expertise of the South San Francisco team, promoting new opportunities for collaborative projects, both internally and with leading global biotech and pharmaceutical companies.

“We’re pleased to announce this strategic acquisition that will bring the exceptional team at Charles River’s South San Francisco site, as well as their cutting-edge technologies, into FairJourney. Said António Parada, CEO, FairJourney Biologics. He continued: “By combining our expertise, we not only strengthen our portfolio with powerful solutions such as the SuperHuman Libraries, but also enhance our ability to deliver innovative solutions to our partners. Working together, we can push the boundaries of antibody discovery and set new industry standards.”

About GHO Capital:
Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. GHO Capital applies global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. GHO Capital’s proven investment track record reflects the unrivalled depth of our industry expertise and network. GHO Capital partners with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare. For further information, please visit www.ghocapital.com.

 

About FairJourney Biologics
FairJourney Biologics is a leading biologics CRO, providing integrated services across antibody discovery, engineering and production to global biopharma. Founded in 2012 and headquartered in Porto, FairJourney has grown to over 90 highly technically skilled employees today. The Company operates a flexible, customer-oriented ‘one-stop shop’ approach to biologics development focused on quality, reliability and partnership. FairJourney has successfully completed more than 460 projects for over 70 customers across big pharma and leading biotech companies to date. The Company’s significant expertise in phage display technology, combined with a diverse approach to generating both immune and naïve antibody libraries have contributed to a market leading 99%+ project success rate. For further information, please visit www.fjb.pt.

Categories: News

Tags:

Ajax Health and KKR Form New Platform to Develop System for Treating Heart Failure

KKR

MENLO PARK, Calif., March 4, 2025 /PRNewswire/ — Ajax Health, a KKR-backed medical device platform, today announced the formation of a new entity, FlowMod. The new organization is the result of a collaboration between Boston Scientific Corporation, Ajax Health, and KKR, utilizing intellectual property developed by Boston Scientific. FlowMod intends to accelerate the creation, clinical validation, and regulatory approval for a system treating heart failure, a condition that affects pumping action of the heart muscles and currently impacts 64 million people worldwide.1

“On the heels of the Cortex transaction with Boston Scientific, we are thrilled to pursue this new path in interventional heart failure and the benefits it may bring to the millions of patients affected by this disease each year,” said Duke Rohlen, Chief Executive Officer, Ajax Health. “Through this collaboration, we intend to bring a differentiated solution to physicians and their patients that we believe will make a positive impact on how heart failure is treated.”

“We are pleased to collaborate with both Ajax Health and Boston Scientific, innovate productively alongside leading strategic partners, and help advance promising medical technology for the benefit of cardiovascular disease patients worldwide,” said Ali Satvat, Partner and Global Head of Health Care Strategic Growth at KKR.

FlowMod will be led by Chief Executive Officer Dr. Philippe Marco, former President and Chief Operations Officer of Epix Therapeutics and CV Ingenuity, both of which were Ajax-led companies that obtained pre-market approval for groundbreaking cardiovascular devices.

“I am excited to work with the Ajax Health and KKR leadership teams again,” said Dr. Marco. “We look forward to developing a meaningful advancement in the treatment of patients with heart failure, building upon the foundation established by Boston Scientific.”

KKR is investing in FlowMod through its KKR Health Care Strategic Growth Fund II, a $4.0 billion fund focused on investing in high-growth health care companies.

About Ajax Health

Ajax Health is a turnkey growth solution for commercial-stage medtech companies. The Ajax team draws on decades of experience as entrepreneurs, operators, and investors to create value for its strategic partners by developing product portfolios through novel business models and creative deal structures. Ajax Health is headquartered in Menlo Park, CA with offices in New York City, Los Angeles, and Austin.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

1 Bozkurt, Biykem et al. HF Stats 2024: Heart Failure Epidemiology and Outcomes Statistics. An Updated 2024 Report from the Heart Failure Society of America. Journal of Cardiac Failure. 2025 Jan; 31(1):66-116.

Media contacts:

For Ajax Health:
Will Kynes
wkynes@ajaxhealth.com

For KKR:
Julia Kosygina
212-750-8300
media@kkr.com

SOURCE Ajax Health

 

Download PDF

Categories: News

Tags:

Novo Holdings participates in $187 million Series A launch financing for Callio Therapeutics to advance innovative dual-payload ADC programs in oncology

Novo Holdings

Investment builds on Novo Holdings’ existing ADC portfolio, leveraging Hummingbird Bioscience’s cutting-edge ADC technology platform.

Newly formed company’s groundbreaking dual-payload ADC programs designed to overcome limitations of existing single-payload therapies.

SINGAPORE and SEATTLE – [March 3, 2025]– Novo Holdings, a leading life science investor today announced that it has invested in a $187M Series A launch financing for Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. In conjunction with the financing, Callio Therapeutics has entered into an exclusive worldwide license agreement with Hummingbird Bioscience, a Novo Holdings portfolio company, for its dual-payload ADC platform in oncology and associated intellectual property and pipeline assets, in exchange for equity, potential milestone payments and royalties.

The oversubscribed Series A financing was led by Frazier Life Sciences, with significant participation from Novo Holdings and other life sciences investors including Jeito Capital, Omega Funds, Norwest, ClavystBio, EDBI, Platanus, Pureos Bioventures and SEEDS Capital.

Headquartered in Seattle and Singapore and launched by Frazier Life Sciences, the newly formed company intends to use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual-payload ADC and a second undisclosed ADC program. The company’s mission aligns with Novo Holdings’ longstanding commitment to advancing innovative ADC technologies and builds on its existing portfolio to support the next generation of precision cancer therapies.

Ken Harrison, Senior Partner, Novo Holdings said: “Novo Holdings is pleased to support Callio Therapeutics to advance its groundbreaking dual-payload ADC programs, leveraging the innovative ADC platform developed by our portfolio company, Hummingbird Bioscience. This investment underscores our commitment to fostering novel oncology therapeutics that have the potential to transform cancer treatment. We look forward to seeing these promising therapies progress through clinical development to benefit cancer patients worldwide.”

In connection with the financing Ken Harrison will join the Callio Therapeutics Board of Directors.

Piers Ingram, PhD, co-founder and Chief Executive Officer, Callio Therapeutics, said: “We are delighted to be launching Callio Therapeutics with the support of Frazier Life Sciences and this syndicate of investors. Multi-payload ADCs have the potential to enable the targeted delivery of rational drug combinations to cancer cells, and may provide significantly enhanced efficacy. This new generation of ADC therapies may meaningfully improve outcomes for patients.”

Adam Simpson, Executive Board Chair, Callio Therapeutics and Venture Partner, Frazier Life Sciences said: “The dual-payload ADCs being developed at Callio Therapeutics have the potential to address large unmet medical needs by overcoming many of the limitations of existing ADCs. With the expertise of the Callio Therapeutics team, together with access to the innovative dual-payload ADC technology, we believe that Callio Therapeutics will be the first company to show the clinical benefit of this exciting new multi-payload ADC approach and is well positioned to transform cancer therapy.”

Led by CEO Pier Ingram, the founding Callio Therapeutics management team comprises individuals with extensive experience from leading biotechnology and biopharmaceutical companies including ProfoundBio, Silverback Therapeutics, SeaGen, Medarex, Hummingbird Bioscience and Genentech:

·       Piers Ingram, PhD, Chief Executive Officer

·       Jerome Boyd-Kirkup, PhD, Chief Scientific Officer

·       Naomi Hunder, MD, Chief Medical Officer

·       Angèle Maki, PhD, Chief Business Officer

 

About Callio Therapeutics
Headquartered in Seattle and Singapore, Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, dual-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of dual agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics’ lead program is a HER2-targeted dual-payload ADC. Callio Therapeutics was created by Frazier Life Sciences, a longstanding investment firm focused on innovative therapeutics, based on ADC technology and programs exclusively in-licensed from Hummingbird Bioscience. For more information , please visit www.calliotx.com and follow Callio Therapeutics on LinkedIn.

About Hummingbird Bioscience
Hummingbird Bioscience is a Singapore-based biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience’s computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube.

About Novo Holdings A/S
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.  Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.  As of year-end 2023, Novo Holdings had total assets of EUR 149 billion.  www.novoholdings.dk

About the Novo Nordisk Foundation
Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people’s health and the sustainability of society and the planet. The Foundation’s mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.

Further information

Dora Gonzalez,
Senior Public Relations Specialist
dopg@novo.dk

Categories: News

Tags:

Novo Holdings and TA Associates partner with Biocomposites to drive next chapter of its growth

Novo Holdings

Additional investment and resources will accelerate Biocomposites’ international expansion and innovation in products for use in infection management

HELLERUP, DENMARK, LONDON and KEELE, UK – 3 March 2025 – Novo Holdings and TA Associates (“TA”), announced today that the parties have entered into an agreement for Novo Holdings to make an investment in Biocomposites (“the Company”), an international medical devices company that engineers, manufactures and markets leading products for use in infection management in bone and soft tissue. As part of the transaction TA, Biocomposites’ majority shareholder since 2017, will reinvest in the Company alongside new investor Novo Holdings and Biocomposites’ management. The transaction gives TA and Novo Holdings shared control of Biocomposites.

Headquartered in Keele, United Kingdom, Biocomposites’ pioneering calcium compounds and specialty polymer products – including STIMULAN, the only calcium matrix carrier platform approved to carry antibiotics into infected and non-infected sites in bone and soft tissue – are trusted by surgeons in over 100 countries worldwide. With over 30 years of expertise, Biocomposites’ advanced solutions are used in more than one million procedures annually, across multiple specialties including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, and sports injuries.

Since partnering with TA in 2017, Biocomposites has achieved significant growth – including a threefold increase in revenues, successful geographic expansion, and continued product diversification. The Company has also completed two strategic acquisitions, strengthening its international presence and enabling entry into adjacent indications and therapeutic areas. With the new investment from Novo Holdings and the ongoing support of TA, Biocomposites aims to build on this momentum, deepening its global footprint and further advancing its pipeline of innovative products to deliver life-changing solutions at scale.

“We are thrilled to partner with Biocomposites and TA in this exciting new chapter for the Company,” said Henrik Kjær Hansen, Senior Partner at Novo Holdings. “Biocomposites’ innovative solutions in infection management align perfectly with our broader portfolio of life sciences investments, and we firmly believe in the Company’s tremendous growth potential. With our deep expertise in life sciences and extensive global network, we look forward to supporting Biocomposites in expanding its international footprint, driving innovation, and advancing its ability to deliver highly effective and targeted infection management solutions that improve patient outcomes worldwide.”

“TA has been a fantastic long-term partner to us, and we are excited for the future alongside them and Novo Holdings,” said Michael Harris, Biocomposites’ CEO. “This investment is a significant validation of Biocomposites’ achievements so far and our future prospects for growth. With the combined expertise and support of these two leading global healthcare investors, we believe we are well positioned to deliver on our commitment to bring ever more innovative products for use in infection management to more people worldwide – transforming patient outcomes and improving their lives.”

“Since our initial investment, Biocomposites has established itself as a pioneer in the infection management space,” said Birker Bahnsen, Managing Director at TA. “The Company has consistently demonstrated its ability to scale internationally while building out a diversified product portfolio that aligns with growing market demand and meets evolving patient needs. It has been a true privilege to take part in Biocomposites’ journey thus far, and we look forward to collaborating closely with the management team and Novo Holdings on this next stage of its growth.”

Financial terms of the transaction were not disclosed. Jefferies International Limited acted as exclusive financial advisor to TA and Biocomposites. Goodwin Procter LLP served as legal counsel to TA and Biocomposites. Kirkland & Ellis International LLP and Linklaters LLP acted as legal advisors to Novo Holdings. Alvarez & Marsal provided Financial and Tax Vendor Due Diligence for Biocomposites, Squire Patton Boggs (UK) LLP (legal), KPMG LLP (UK) (tax) and Jamieson Corporate Finance (management advisory) acted for Biocomposites Management.

 

About Biocomposites
Biocomposites is an international medical devices company that engineers, manufactures, and markets world leading products for use in infection management in bone and soft tissue. Based in Keele, UK, it has global operations across Europe, USA, Argentina, Canada, China, and India. Biocomposites is a leading developer of innovative calcium compounds and bone cements for surgical use. Its products regenerate bone and target infection risks across a variety of specialties, including musculoskeletal infection, orthopaedics, trauma, spine, foot and ankle, podiatry, and sports injuries. Biocomposites products are now used in over one million procedures per annum and sold in more than 100 countries around the world. Please visit biocomposites.com to learn more.

About TA Associates
TA is a leading global private equity firm focused on scaling growth in profitable companies. Since 1968, TA has invested in more than 560 companies across its five target industries – technology, healthcare, financial services, consumer and businesses services. Leveraging its deep industry expertise and strategic resources, TA collaborates with management teams worldwide to help high-quality companies deliver lasting value. The firm has raised $65 billion in capital to date and has more than 160 investment professionals across offices in Boston, Menlo Park, Austin, London, Mumbai and Hong Kong. Further information on TA can be found at www.ta.com.

About Novo Holdings
Novo Holdings is a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novonesis and manages an investment portfolio with a long-term return perspective. Novo

Holdings invests in life science companies at all stages of development and also manages a broad portfolio of equities, bonds, real estate and infrastructure assets as well as private equity investments.

As of year-end 2023, Novo Holdings had total assets of €149 billion. Further information: www.novoholdings.dk.

Further information

Biocomposites
Optimum Strategic Communications
Mary Clark, Stephen Adams, Katie Flint
Tel: +44 (0)20 3882 9621
biocomposites@optimumcomms.com

TA Associates
Maggie Benoit
mbenoit@ta.com

Novo Holdings
Christian Mostrup
Director, Public Relations
+ 45 30674805
cims@novo.dk

Categories: News

Tags:

Blackstone Announces Agreement to Acquire a Majority Stake in CMIC Co., Ltd., Japan’s Leading Contract Research Organization, Continuing Robust Deal Momentum in Japan

Blackstone

Tokyo – March 3, 2025 – Blackstone (NYSE:BX) announced today that private equity funds managed by Blackstone (“Blackstone”) have entered into a definitive agreement to acquire a majority stake in CMIC Co., Ltd. (“CMIC” or “the Company”), Japan’s leading contract research organization (CRO) that provides comprehensive end-to-end services across clinical trial phases and therapeutic areas. Blackstone will acquire a 60% stake while CMIC HOLDINGS Co., Ltd. (“CMIC HD”) will retain the remaining 40% stake in the Company.

This investment underscores Blackstone’s commitment to investing in Japan’s healthcare services sector, where it has deep expertise and network.

Atsuhiko Sakamoto, Head of Private Equity, Blackstone Japan, said: “This is a continuation of our strong commitment to Japan – one of our fastest-growing markets globally – and investing in our high conviction theme, life-sciences-related services, where we’ve built a meaningful portfolio in Japan and around the world. We’re focused on bringing critical medicines and technologies to the Japanese market and helping transform the industry and patients’ lives. We’re proud to showcase a hallmark Blackstone deal: partnering with a visionary founder and the management team to help build the business for lasting value, benefitting from our scale, operational expertise, and synergy across our portfolio.”

CMIC was founded in 1992 as the first CRO in Japan. It has pioneered the sector, partnering with pharmaceutical and biotechnology companies to help develop medicines and bring them to the market faster and more efficiently.

Kazuo Nakamura, Founder, Chairman & Chief Executive Officer, CMIC HD, said: “We are thrilled to partner with Blackstone, the world’s leading alternative investor, and continue CMIC’s growth. CMIC, as the first pioneer, brings 33 years of industry heritage and has become the top player in Asia, serving as a critical partner to healthcare and pharmaceutical institutions, individuals, and the government. We couldn’t be prouder of how the Company is positioned today and expect Blackstone to play a key role in further unlocking the Company’s potential.”

Blackstone had one of its most active years in Japan last year. In Private Equity, Blackstone announced four landmark transactions including I’rom Group, Japan’s leading SMO; Infocom, the leading provider of digital comics in one of the largest deals in 2024; Sony Payment Services, a carveout of Sony’s payment service provider; and the sale of Alinamin after transforming the company into a market leader. In Real Estate, Blackstone announced the acquisition of Tokyo Garden Terrace Kioicho, Japan’s largest real estate investment ever by a foreign investor.

About Blackstone
Blackstone is the world’s largest alternative asset manager. We seek to deliver compelling returns for institutional and individual investors by strengthening the companies in which we invest. Our more than $1.1 trillion in assets under management include global investment strategies focused on real estate, private equity, infrastructure, life sciences, growth equity, credit, real assets, secondaries and hedge funds. Further information is available at www.blackstone.com. Follow @blackstone on LinkedIn, X (Twitter), and Instagram.

Media Contact
Mariko Sanchanta
mariko.sanchanta@blackstone.com
080 8702 7386

Minako Otani
blackstone@kekstcnc.com
+81 (0)3 5156 0190
+81 (0) 90 3239 9348

Categories: News

Tags:

KKR Provides Bespoke Financing Solution to Australian GP Group Family Doctor

KKR

SYDNEY–(BUSINESS WIRE)– KKR, a leading global investment firm, and Family Doctor Pty Ltd. (“Family Doctor”), a leading group of general practitioner (“GP”) clinics in Australia, today announced a bespoke financing solution by KKR (through funds managed by KKR) to Family Doctor. KKR’s bespoke financing solution positions the Family Doctor to accelerate its growth and expansion, including through acquisitions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250302805504/en/

Founded in 2008, Family Doctor provides comprehensive medical care services through its network of more than 110 GP-run clinics located in key metropolitan and regional areas across Australia, including Victoria, Queensland, Western Australia, New South Wales, the Australian Capital Territory, and South Australia.

KKR’s Asia Pacific Credit platform seeks to provide, among other private credit strategies, bespoke solutions to high-quality companies, entrepreneurs and sponsors that harness the strength of KKR’s private markets investment capabilities and its expertise as one of the largest alternative credit managers globally. These bespoke structures allow entrepreneurs to retain equity ownership and control in their businesses whilst accessing deep capital pools that allow them to meet their objectives to invest in growth or return capital to shareholders.

Diane Raposio, Partner and Head of Asia Credit and Markets, KKR, said, “We are pleased to provide a bespoke financing solution to Family Doctor and Dr. Aziz, who has established one of Australia’s leading networks of GP clinics. Our investment builds on our experience and ability to work with homegrown champions and entrepreneurs in Australia, a key market for KKR across multiple private credit strategies. We look forward to sharing our global network and expertise to support the Company on their mission to extend high-quality patient care and their expansion plans.”

Dr. Rodney Aziz, Founder, CEO and Principal GP at Family Doctor, said, “Over the last more than 17 years, we have grown from a single clinic to one of Australia’s largest medical centre groups. The bespoke financing solution provided by KKR allows Family Doctor to stay true to our mission of being 100% doctor-owned and providing quality care and services. As we look forward to scaling our impact and our next phase of growth, we are delighted to collaborate with KKR on a flexible finance solution that not only is tailored to our stage of growth but also brings KKR’s global knowledge and know-how to our platform.”

KKR is making its investment from its Asia Pacific Credit strategy. In Australia, KKR has provided bespoke solutions to DBG Health (a leading pharmaceutical company) and Lendi (a leading fintech), and financings to companies and sponsors across a range of industries and private credit strategies. Since 2019, KKR has closed more than 50 credit investments in Asia Pacific, accounting for a total transaction value of close to US$21 billion.

***

About Family Doctor

Family Doctor is a 100% GP owned group of 110 medical and dental practices across Australia enabling delivery of 3.2 million high quality medical consultations to Australians in metro and regional areas each year. Family Doctor is the fastest growing medical group in Australia, and is keen to support like-minded practice owners with their succession planning.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

Media Inquiries

For more information, please contact:

For Family Doctor
Dr Rodney Aziz, CEO and Principal GP
+61 03 8592 9855
rod@familydoctor.com.au

For KKR
Wei Jun Ong
+65 6922 5813
WeiJun.Ong@kkr.com

Source: KKR & Co. Inc.

 

Download PDF

 

Categories: News

Tags:

Julius Clinical Strengthens its European Capabilities by Expanding Operations in Poland

Ampersand

Zeist, Netherlands, February 25, 2025 – Julius Clinical, a science-driven global CRO specializing in Neurological, Cardio-Metabolic, Renal and Rare Diseases, is pleased to announce the establishment of Julius Clinical Poland, a new operational hub in Krakow. This expansion reinforces Julius Clinical’s position as a global leader in CNS and Cardio-Metabolic research while enhancing its pan-European capabilities in clinical trials.

With a strong track record of over 15 clinical trials conducted in Poland during the last years, Julius Clinical recognizes the country’s exceptional potential as a key clinical research hub in Europe. Poland offers a highly skilled workforce, a robust healthcare infrastructure, and a proven commitment to clinical research, making it an optimal destination for expanding the company’s European footprint. The new affiliate will enable more efficient patient recruitment, improved site selection, and seamless regulatory compliance, ultimately accelerating the development of innovative therapies.

Martijn Wallert, CEO of Julius Clinical, said: “Expanding into Poland marks a strategic milestone for Julius Clinical. We are strengthening our presence in Eastern Europe, making Poland a central hub for our regional operations and expanding our ability to support clinical research across neighboring countries.”

Radek Korba, Country Manager Poland, brings long-standing collaboration experience with Julius Clinical, ensuring a smooth transition for customers and partners. “Poland is a pivotal market in clinical research, and our local presence allows us to drive innovation while maintaining the highest standards of quality and compliance. We are excited to strengthen collaborations with investigators, healthcare institutions, and regulatory bodies to deliver impactful research,” said Korba.

Julius Clinical’s expansion into Poland aligns with its broader strategy of providing world-class, scientifically driven clinical research services globally. With this move, the company reinforces its commitment to accelerating medical breakthroughs through cutting-edge trial designs, access to diverse patient populations, and deep scientific expertise.

Julius Clinical is supported by Ampersand Capital Partners, a leading private equity firm with deep expertise in the life sciences and healthcare sectors.

About Julius Clinical

Founded in 2008 and headquartered in Zeist, The Netherlands, Julius Clinical is a leading CRO specializing in CNS, Cardio-Metabolic, Renal, and Rare Diseases. With over 380 clinical trials and 220,000+ subjects across 39 countries, Julius Clinical combines scientific leadership, operational excellence, and a global network of research sites to deliver tailored solutions for pharmaceutical, biotechnology, and academic partners.

For more information, visit https://www.juliusclinical.com or follow us on LinkedIn.

About Ampersand Capital Partners

Ampersand Capital Partners, founded in 1988, is a middle-market private equity firm with $3 billion of assets under management, dedicated to growth-oriented investments in the healthcare sector. With offices in Boston, MA, and Amsterdam, The Netherlands, Ampersand leverages a unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm’s core healthcare sectors.

For additional information, visit https://ampersandcapital.com or follow us on LinkedIn.

For more information on Julius Clinical services:

Email: businessdevelopment@juliusclinical.com

For more information on this press release, please contact:

Toni Kovandjieva

Marketing Manager, Julius Clinical

Email: toni.kovandjieva@juliusclinical.com

Categories: News

Tags:

CVC agrees the sale of up to 54% stake in Healthcare Global Enterprises for up to US$400m

CVC Capital Partners

CVC, a leading global private markets manager, is pleased to announce the signing of definitive agreements for the sale of CVC Asia V’s majority stake in Healthcare Global Enterprises (“HCG”), a leading healthcare organization in India, to KKR. CVC Asia V will sell up to a 54% stake in HCG to funds managed by KKR, a leading global investment firm, at a purchase price of INR 445 per share.

Following the completion of the transaction Dr. BS Ajai Kumar, Founder of HCG, will take on the role of Non-Executive Chairman and will focus on driving clinical, academic and R&D excellence.

Founded in 1989, HCG is one of India’s largest oncology hospital chains. HCG operates 25 medical care centres across 19 cities with best-in-class infrastructure including 2,500 beds, nearly 100 operating theatres and 40 linear accelerator machines (LINACs). Since CVC Asia V invested in 2020, CVC’s India team have worked closely with HCG on a transformational value creation program to drive revenue growth through and beyond COVID, improve key performance indicators, source and execute acquisitions and digital transformation, whilst ensuring continuous improvement in patient care and clinical outcomes.

Siddharth Patel, Managing Partner at CVC said: “We are proud to have supported HCG’s transformation at a critical juncture in time to build it into one of India’s leading healthcare organizations and the delivery of high-quality care to many patients over the years.”

Quotes

“We are proud to have supported HCG’s transformation at a critical juncture in time to build it into one of India’s leading healthcare organizations and the delivery of high-quality care to many patients over the years.”

Siddharth PatelManaging Partner at CVC

Amit Soni, Partner at CVC added: “Our partnership with Dr. Ajaikumar and the management team is a testimony to our ability to combine clinical and professional acumen to increase the reach of cancer care in India. We thank Dr. Ajai and the management for their unparalleled support and commitment to a common vision.”

Dr. BS Ajaikumar, Founder, HCG, said, “I want to thank CVC for their support through the years, helping the management to put HCG in the strong position it is in today. I am delighted to welcome KKR, with their investment and operational expertise in healthcare in India and globally, as a majority shareholder in HCG. Patient wellbeing and outcomes will always be a top priority for us at HCG, and in my new role as Non-Executive Chairman, I would focus on clinical aspects involving multi-disciplinary approach to cancer care, and research and development; and look forward to the journey of HCG where it continues to stay at the forefront of clinical excellence, research, and academics.”

The transaction is expected to close in Q3 2025, subject to customary closing conditions and regulatory approvals.

Categories: News

Tags: